Amyris Acquires MenoLabs

April 12, 2022

Amyris, a publicly traded synthetic biotechnology company, has acquired MenoLabs, a DTC women's wellness brand focused on perimenopause and menopause supplements and a symptom-tracking app. The deal is intended to accelerate Amyris' position in the menopause market by combining MenoLabs' subscription-based consumer business, app data, and product formulations with Amyris' fermentation technology and consumer brand capabilities.

Buyers
Amyris
Targets
MenoLabs
Sellers
Owners of MenoLabs (founders/management team)
Location
United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.